Advances in Studies on the Effect of Incretin-Based Therapy on Cardiovascular System
10.3969/j.issn.0253-9896.2014.11.028
- VernacularTitle:基于肠促胰素的治疗药物在心血管系统中作用的研究进展
- Author:
Qian YU
;
Demin YU
- Publication Type:Journal Article
- Keywords:
diabetes mellitus,type 2;
cardiovascular disease;
glucagon-like peptide 1;
enzyme dipeptidyl peptidases
- From:
Tianjin Medical Journal
2014;(11):1144-1148
- CountryChina
- Language:Chinese
-
Abstract:
Cardiovascular disease (CVD) is one of the major complications of type 2 diabetes mellitus (T2DM), which results in a high risk of mortality. Thus, the cardiovascular safety of new anti-diabetic agents has become an important prob?lem with wide concern. There are two classes of incretine-based medications: glucagon-like peptide-1 receptor agonist (GLP-1RA) and dipeptidyl peptidase-4 (DPP-4) inhibitor (DPP-4I). It has been demonstrated that GLP-1RA and DPP-4I possesse beneficial actions in both animal models of cardiovascular dysfunction and patients with ischemic heart diseases. However, their effects on the cardiovascular system in diabetic patients with heart diseases are still uncertain. Here, we sys?tematically reviewed the effects of GLP-1RA and DPP-4I on cardiovascular system to provide more evidence of incretin-based therapy application for diabetes and complications.
